{"company":{"id":2510878,"name":"Adapt Immune","domain":"adaptimmune.com","url":"https://alion.io/company/adaptimmune"},"section":"news","answer":"Adapt Immune: 13 headlines on record, 0 headlines in the last 90 days. Its story counts 10 milestones.","figures":[{"label":"Headlines","value":"13"},{"label":"In 90 days","value":"0"},{"label":"Milestones","value":"10"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":13},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":10}],"news":[{"date":"2025-11-17","kind":"Press release","title":"Adaptimmune Announces Changes to Board and Executive Leadership Team","url":"https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/290/adaptimmune-announces-changes-to-board-and-executive"},{"date":"2025-10-20","kind":"Press release","title":"Adaptimmune Announces Delisting from Nasdaq","url":"https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/289/adaptimmune-announces-delisting-from-nasdaq"},{"date":"2025-08-13","kind":"Press release","title":"Adaptimmune Reports Q2 Financial Results and Provides Business Update","url":"https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/288/adaptimmune-reports-q2-financial-results-and-provides"},{"date":"2025-07-28","kind":"News","title":"Adaptimmune, seeking to stay afloat, sells off cell therapies","source":"YahooFinance","url":"https://finance.yahoo.com/news/adaptimmune-seeking-stay-afloat-sells-162000183.html"},{"date":"2025-07-28","kind":"Press release","title":"Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds","url":"https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/287/adaptimmune-announces-entry-into-definitive-agreement-for"},{"date":"2025-05-13","kind":"Press release","title":"Adaptimmune Reports Q1 Financial Results and Provides Business Update","url":"https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/286/adaptimmune-reports-q1-financial-results-and-provides"},{"date":"2025-05-07","kind":"Press release","title":"Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025","url":"https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/285/adaptimmune-to-report-q1-2025-financial-and-business"},{"date":"2025-03-20","kind":"Press release","title":"Adaptimmune Provides Q4 and Full Year 2024 Business Update","url":"https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/284/adaptimmune-provides-q4-and-full-year-2024-business-update"},{"date":"2025-03-12","kind":"Press release","title":"Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025","url":"https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/283/adaptimmune-to-report-full-year-and-q4-2024-financial-and"},{"date":"2025-01-31","kind":"Press release","title":"Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025","url":"https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/282/adaptimmune-to-participate-in-the-guggenheim-securities"},{"date":"2025-01-13","kind":"Press release","title":"Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)","url":"https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/281/adaptimmune-announces-u-s-fda-breakthrough-therapy"},{"date":"2024-10-08","kind":"News","title":"A Navy Yard biotech designed a first-of-its-kind therapy for rare cancer. Now, it waits for patients.","source":"The Philadelphia Inquirer, LLC","url":"https://inquirer.com/health/philadelphia-biotech-adaptimmune-cancer-tecelra-synovial-sarcoma-20241008.html"},{"date":"2024-08-03","kind":"News","title":"Adaptimmune's FDA Approval Marks the First for an Engineered Cell Therapy for Solid Tumors","source":"MedCity News","url":"https://medcitynews.com/2024/08/cell-therapy-solid-tumor-adaptimmune-tcr-synovial-sarcoma-fda-approval-adap/"}],"story":[{"title":"Raised a round Venture round","url":"https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzExMDU4MTQ1M2FkaXF6a2N4"},{"title":"Raised a round Venture round","url":"https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzEwMTMyNTc2M2FkaXF6a2N4"},{"title":"Raised a round Venture round","url":"https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzA4MTg3MDQ1MmFkaXF6a2N4"},{"title":"Raised a round Venture round","url":"https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzA2NzgxNDc5NWFkaXF6a2N4"},{"title":"Raised a round Venture round","url":"https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzA2MDc1NzE2M2FkaXF6a2N4"},{"title":"Raised a round Venture round","url":"https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzA1MTU1MTQ0NmFkaXF6a2N4"},{"title":"Raised a round Venture round","url":"https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzA0MTg3MTM3MGFkaXF6a2N4"},{"title":"Raised a round Venture round","url":"https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzAzMTc2MTIyOWFkaXF6a2N4"},{"title":"Raised a round Venture round","url":"https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzAzMTM1NDQ5MGFkaXF6a2N4"},{"title":"Raised a round Venture round","url":"https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzAxODI3MTkwM2FkaXF6a2N4"}],"as_of":"2026-11-17","cite":"Adapt Immune, News. Alion, Nov 17, 2026. https://alion.io/company/adaptimmune/news","html_url":"https://alion.io/company/adaptimmune/news","json_url":"https://alion.io/company/adaptimmune/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-17T22:42:34Z"}}